A phase 2 pilot study of the safety, pharmacokinetics, and pharmacodynamics of ARC1779 injection in patients with von Willebrand factor-related platelet function disorders.

Trial Profile

A phase 2 pilot study of the safety, pharmacokinetics, and pharmacodynamics of ARC1779 injection in patients with von Willebrand factor-related platelet function disorders.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2012

At a glance

  • Drugs Egaptivon pegol (Primary) ; Desmopressin
  • Indications Embolism and thrombosis; Thrombotic thrombocytopenic purpura; Von Willebrand disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jun 2012 Company added in the association field as reported by EudraCT.
    • 01 Dec 2008 Status changed from recruiting to completed, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top